Cardiac matrix: A clue for future therapy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 2271-2276

  Mishra, Paras Kumar ^a   Givvimani, Srikanth ^b   Chavali, Vishalakshi ^a   Tyagi, Suresh C ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Angiogenesis; Heart; MiRNA; MMP; Stem cell; TIMP

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ANGIOSTATIN; BATIMASTAT; ENDOSTATIN; GELATINASE A; GELATINASE B; ILOMASTAT; MARIMASTAT; MICRORNA; PROTEINASE; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ACUTE CORONARY SYNDROME; AGING; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTERY WALL; ATHEROSCLEROSIS; AUTOPHAGY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DNA METHYLATION; DOWN REGULATION; ENDOCARDIUM; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LUNG EMBOLISM; MICROENVIRONMENT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOSIS; UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 84884792184     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.09.004     Document Type: Review

References (76)

1. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
2. Gilbert P.M., Havenstrite K.L., Magnusson K.E., Sacco A., Leonardi N.A., Kraft P., Nguyen N.K., Thrun S., Lutolf M.P., Blau H.M. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010, 329:1078-1081.
3. Kajstura J., Hosoda T., Bearzi C., Rota M., Maestroni S., Urbanek K., Leri A., Anversa P. The human heart: a self-renewing organ. Clin. Transl. Sci. 2008, 1:80-86.
4. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F., Ikram S., Beache G.M., Wagner S.G., Leri A., Hosoda T., Sanada F., Elmore J.B., Goichberg P., Cappetta D., Solankhi N.K., Fahsah I., Rokosh D.G., Slaughter M.S., Kajstura J., Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
5. Hu S., Huang M., Nguyen P.K., Gong Y., Li Z., Jia F., Lan F., Liu J., Nag D., Robbins R.C., Wu J.C. Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation. Circulation 2011, 124:S27-S34.
6. Tyagi A.C., Sen U., Mishra P.K. Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases. Curr. Diabetes Rev. 2011, 7:367-376.
7. Mishra P.K., Metreveli N., Tyagi S.C. MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA. Cell Biochem. Biophys. 2010, 57:67-76.
8. Mishra P.K., Chavali V., Metreveli N., Tyagi S.C. Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix. Can. J. Physiol. Pharmacol. 2012, 90:353-360.
9. Mishra P.K., Tyagi N., Sen U., Joshua I.G., Tyagi S.C. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. Cardiovasc. Diabetol. 2010, 9:49.
10. Tyagi S.C., Ratajska A., Weber K.T. Myocardial matrix metalloproteinase(s): localization and activation. Mol. Cell. Biochem. 1993, 126:49-59.
11. Dhanaraj V., Ye Q.Z., Johnson L.L., Hupe D.J., Ortwine D.F., Dunbar J.B., Rubin J.R., Pavlovsky A., Humblet C., Blundell T.L. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996, 4:375-386.
12. Bernstein M., Sloutskis D., Kumanyika S., Sparti A., Schutz Y., Morabia A. Data-based approach for developing a physical activity frequency questionnaire. Am. J. Epidemiol. 1998, 147:147-154.
13. Moshal K.S., Tyagi N., Moss V., Henderson B., Steed M., Ovechkin A., Aru G.M., Tyagi S.C. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J. Cell. Mol. Med. 2005, 9:704-713.
14. Moshal K.S., Tipparaju S.M., Vacek T.P., Kumar M., Singh M., Frank I.E., Patibandla P.K., Tyagi N., Rai J., Metreveli N., Rodriguez W.E., Tseng M.T., Tyagi S.C. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H890-H897.
15. Moshal K.S., Metreveli N., Frank I., Tyagi S.C. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr. Vasc. Pharmacol. 2008, 6:84-92.
16. Givvimani S., Tyagi N., Sen U., Mishra P.K., Qipshidze N., Munjal C., Vacek J.C., Abe O.A., Tyagi S.C. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch. Physiol. Biochem. 2010, 116:63-72.
17. Ma Z., Chang M.J., Shah R., Adamski J., Zhao X., Benveniste E.N. Brg-1 is required for maximal transcription of the human matrix metalloproteinase-2 gene. J. Biol. Chem. 2004, 279:46326-46334.
18. Qin H., Sun Y., Benveniste E.N. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J. Biol. Chem. 1999, 274:29130-29137.
19. Gutierrez F.R., Lalu M.M., Mariano F.S., Milanezi C.M., Cena J., Gerlach R.F., Santos J.E., Torres-Duenas D., Cunha F.Q., Schulz R., Silva J.S. Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. J. Infect. Dis. 2008, 197:1468-1476.
20. Wang G.Y., Bergman M.R., Nguyen A.P., Turcato S., Swigart P.M., Rodrigo M.C., Simpson P.C., Karliner J.S., Lovett D.H., Baker A.J. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc. Res. 2006, 69:688-696.
21. Li Z., Li L., Zielke H.R., Cheng L., Xiao R., Crow M.T., Stetler-Stevenson W.G., Froehlich J., Lakatta E.G. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am. J. Pathol. 1996, 148:121-128.
22. Lovett D.H., Mahimkar R., Raffai R.L., Cape L., Maklashina E., Cecchini G., Karliner J.S. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 2012, 7:e34177.
23. Libby P., Lee R.T. Matrix matters. Circulation 2000, 102:1874-1876.
24. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
25. Spoto B., Testa A., Parlongo R.M., Tripepi G., D'Arrigo G., Mallamaci F., Zoccali C. Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. Nephrol. Dial. Transplant. 2012, 27:2440-2445.
26. Seo D.W., Saxinger W.C., Guedez L., Cantelmo A.R., Albini A., Stetler-Stevenson W.G. An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. Peptides 2011, 32:1840-1848.
27. Seo D.W., Li H., Guedez L., Wingfield P.T., Diaz T., Salloum R., Wei B.Y., Stetler-Stevenson W.G. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114:171-180.
28. Kallio J.P., Hopkins-Donaldson S., Baker A.H., Kahari V.M. TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. Int. J. Cancer 2011, 128:991-996.
29. Finan K.M., Hodge G., Reynolds A.M., Hodge S., Holmes M.D., Baker A.H., Reynolds P.N. In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer 2006, 53:273-284.
30. Koskivirta I., Kassiri Z., Rahkonen O., Kiviranta R., Oudit G.Y., McKee T.D., Kyto V., Saraste A., Jokinen E., Liu P.P., Vuorio E., Khokha R. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J. Biol. Chem. 2010, 285:24487-24493.
31. Ahmed S.H., Clark L.L., Pennington W.R., Webb C.S., Bonnema D.D., Leonardi A.H., McClure C.D., Spinale F.G., Zile M.R. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113:2089-2096.
32. Spinale F.G., Janicki J.S., Zile M.R. Membrane-associated matrix proteolysis and heart failure. Circ. Res. 2013, 112:195-208.
33. Peterson J.T., Hallak H., Johnson L., Li H., O'Brien P.M., Sliskovic D.R., Bocan T.M., Coker M.L., Etoh T., Spinale F.G. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303-2309.
34. Rizzi E., Castro M.M., Prado C.M., Silva C.A., Fazan R., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J. Card. Fail. 2010, 16:599-608.
35. Rizzi E., Ceron C.S., Guimaraes D.A., Prado C.M., Rossi M.A., Gerlach R.F., Tanus-Santos J.E. Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-beta in renovascular hypertension-induced cardiac hypertrophy. Exp. Mol. Pathol. 2013, 94:1-9.
36. Ferraz K.C., Sousa-Santos O., Neto-Neves E.M., Rizzi E., Muniz J.J., Gerlach R.F., Tanus-Santos J.E. Recombinant human matrix metalloproteinase-2 impairs cardiovascular beta-adrenergic responses. Basic Clin. Pharmacol. Toxicol. 2013, 112:103-109.
37. Phatharajaree W., Phrommintikul A., Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can. J. Cardiol. 2007, 23:727-733.
38. Neto-Neves E.M., Kiss T., Muhl D., Tanus-Santos J.E. Matrix metalloproteinases as drug targets in acute pulmonary embolism. Curr. Drug Targets 2013, 14:344-352.
39. Neto-Neves E.M., Dias-Junior C.A., Rizzi E., Castro M.M., Sonego F., Gerlach R.F., Tanus-Santos J.E. Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit. Care Med. 2011, 39:349-356.
40. Sousa-Santos O., Neto-Neves E.M., Ferraz K.C., Ceron C.S., Rizzi E., Gerlach R.F., Tanus-Santos J.E. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385:685-696.
41. Castro M.M., Kandasamy A.D., Youssef N., Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol. Res. 2011, 64:551-560.
42. Yamada A., Uegaki A., Nakamura T., Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm. Res. 2000, 49:144-146.
43. Golub L.M., McNamara T.F., D'Angelo G., Greenwald R.A., Ramamurthy N.S. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J. Dent. Res. 1987, 66:1310-1314.
44. Richards C., Pantanowitz L., Dezube B.J. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials. Pharmacol. Res. 2011, 63:151-156.
45. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
46. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
47. Mishra P.K., Tyagi N., Kumar M., Tyagi S.C. MicroRNAs as a therapeutic target for cardiovascular diseases. J. Cell. Mol. Med. 2009, 13:778-789.
48. Pelouch V., Dixon I.M., Golfman L., Beamish R.E., Dhalla N.S. Role of extracellular matrix proteins in heart function. Mol. Cell. Biochem. 1993, 129:101-120.
49. Tyagi S.C. Proteinases and myocardial extracellular matrix turnover. Mol. Cell. Biochem. 1997, 168:1-12.
50. Tyagi S.C., Kumar S.G., Haas S.J., Reddy H.K., Voelker D.J., Hayden M.R., Demmy T.L., Schmaltz R.A., Curtis J.J. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J. Mol. Cell. Cardiol. 1996, 28:1415-1428.
51. Felkin L.E., Birks E.J., George R., Wong S., Khaghani A., Yacoub M.H., Barton P.J. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J. Heart Lung Transplant. 2006, 25:1413-1419.
52. Ovechkin A.V., Tyagi N., Rodriguez W.E., Hayden M.R., Moshal K.S., Tyagi S.C. Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J. Appl. Physiol. 2005, 99:2398-2405.
53. Pavlovsky A.G., Williams M.G., Ye Q.Z., Ortwine D.F., Purchase C.F., White A.D., Dhanaraj V., Roth B.D., Johnson L.L., Hupe D., Humblet C., Blundell T.L. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci. 1999, 8:1455-1462.
54. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., Bang M.L., Segnalini P., Gu Y., Dalton N.D., Elia L., Latronico M.V., Hoydal M., Autore C., Russo M.A., Dorn G.W., Ellingsen O., Ruiz-Lozano P., Peterson K.L., Croce C.M., Peschle C., Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007, 13:613-618.
55. Matkovich S.J., Wang W., Tu Y., Eschenbacher W.H., Dorn L.E., Condorelli G., Diwan A., Nerbonne J.M., Dorn G.W. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ. Res. 2010, 106:166-175.
56. Chavali V., Tyagi S.C., Mishra P.K. MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem. Biophys. Res. Commun. 2012, 425:668-672.
57. Mishra P.K., Singh S.R., Joshua I.G., Tyagi S.C. Stem cells as a therapeutic target for diabetes. Front. Biosci. 2010, 15:461-477.
58. Eitan Y., Sarig U., Dahan N., Machluf M. Acellular cardiac extracellular matrix as a scaffold for tissue engineering: in vitro cell support, remodeling, and biocompatibility. Tissue Eng. Part C Methods 2010, 16:671-683.
59. Friehs I., Margossian R.E., Moran A.M., Cao-Danh H., Moses M.A., del Nido P.J. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res. Cardiol. 2006, 101:204-213.
60. Sang Q.X. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998, 8:171-177.
61. Brooks P.C., Silletti S., von Schalscha T.L., Friedlander M., Cheresh D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92:391-400.
62. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
63. Sodha N.R., Clements R.T., Boodhwani M., Xu S.H., Laham R.J., Bianchi C., Sellke F.W. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H428-H434.
64. Laham R.J., Sellke F.W., Edelman E.R., Pearlman J.D., Ware J.A., Brown D.L., Gold J.P., Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999, 100:1865-1871.
65. Rosengart T.K., Lee L.Y., Patel S.R., Kligfield P.D., Okin P.M., Hackett N.R., Isom O.W., Crystal R.G. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 1999, 230:466-470.
66. Schumacher B., Pecher P., von Specht B.U., Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998, 97:645-650.
67. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., Colucci W.S., Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005, 115:2108-2118.
68. Givvimani S., Munjal C., Gargoum R., Sen U., Tyagi N., Vacek J.C., Tyagi S.C. Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J. Appl. Physiol. 2011, 110:1093-1100.
69. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., Schoen F.J., Kelly R.A., Werb Z., Libby P., Lee R.T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 2000, 106:55-62.
70. Hua J.Y., Zhang Z.C., Jiang X.H., He Y.Z., Chen P. Relationship between endothelial-to-mesenchymal transition and cardiac fibrosis in acute viral myocarditis. Zhejiang Da Xue Xue Bao Yi Xue Ban 2012, 41:298-304.
71. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
72. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., Chandraker A., Yuan X., Pu W.T., Roberts A.B., Neilson E.G., Sayegh M.H., Izumo S., Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
73. Yang J., Shultz R.W., Mars W.M., Wegner R.E., Li Y., Dai C., Nejak K., Liu Y. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J. Clin. Invest. 2002, 110:1525-1538.
74. Lefer D.J. A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:17907-17908.
75. Qipshidze N., Metreveli N., Mishra P.K., Lominadze D., Tyagi S.C. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int. J. Biol. Sci. 2012, 8:430-441.
76. Lin Y.D., Luo C.Y., Hu Y.N., Yeh M.L., Hsueh Y.C., Chang M.Y., Tsai D.C., Wang J.N., Tang M.J., Wei E.I., Springer M.L., Hsieh P.C. Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair. Sci. Transl. Med. 2012, 4:146ra109.